Albany Molecular Research (NASDAQ: AMRI) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.
Insider and Institutional Ownership
72.1% of Albany Molecular Research shares are owned by institutional investors. Comparatively, 93.9% of ACADIA Pharmaceuticals shares are owned by institutional investors. 14.5% of Albany Molecular Research shares are owned by insiders. Comparatively, 22.3% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This table compares Albany Molecular Research and ACADIA Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Albany Molecular Research||N/A||N/A||N/A||($1.43)||-15.20|
|ACADIA Pharmaceuticals||$17.33 million||218.53||-$271.39 million||($2.45)||-12.44|
Albany Molecular Research has higher earnings, but lower revenue than ACADIA Pharmaceuticals. Albany Molecular Research is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Albany Molecular Research has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 3.8, meaning that its stock price is 280% more volatile than the S&P 500.
This is a breakdown of current ratings and recommmendations for Albany Molecular Research and ACADIA Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Albany Molecular Research||0||4||0||0||2.00|
Albany Molecular Research currently has a consensus price target of $18.00, suggesting a potential downside of 17.20%. ACADIA Pharmaceuticals has a consensus price target of $49.42, suggesting a potential upside of 62.07%. Given ACADIA Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe ACADIA Pharmaceuticals is more favorable than Albany Molecular Research.
This table compares Albany Molecular Research and ACADIA Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Albany Molecular Research||-5.93%||-13.39%||-3.42%|
ACADIA Pharmaceuticals beats Albany Molecular Research on 7 of the 11 factors compared between the two stocks.
Albany Molecular Research Company Profile
Albany Molecular Research, Inc. is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing. The API segment includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates. The DP segment includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized sterile injectable products and ophthalmic formulations. The FC segment includes lab to commercial scale synthesis of reagents and diverse compounds. It supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs.
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer’s disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.
Receive News & Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related companies with MarketBeat.com's FREE daily email newsletter.